Marker Therapeutics MRKR
NASDAQ MRKR
$1.07 -0.06 (-5.31%)
At close: Oct 22, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022)

Updated

Marker Therapeutics (MRKR) recorded Liabilities from Discontinued Operations of $7.04 million in Q4 2022.

Analysis

Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Marker Therapeutics 17.87 Mn -42.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 7.04 Mn
API Access

Marker Therapeutics Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=MRKR&period=max&api_key=YOUR_API_KEY